0.2400
+0.0400
+(20.00%)
At close: January 10 at 3:58:55 PM EST
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Thomas A. Smeenk B.A., BA Hons | Co-Founder, President, CEO & Director | 308k | -- | 1962 |
| Ms. Christina Wu CPA | Interim Chief Financial Officer | 65.38k | -- | -- |
| Mr. Peter Pavlin | Vice President of Operations | -- | -- | -- |
| Dr. Fraser C. Henderson Sr., M.D. | Chief Medical Officer | -- | -- | -- |
Hemostemix Inc.
707-7th Avenue SW
Suite 1150
Calgary, AB T2P 3H6
Canada
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Corporate Governance
Hemostemix Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 29, 2024 at 1:30 PM UTC
Hemostemix Inc. Earnings Date
Recent Events
December 30, 2020 at 12:00 AM UTC
Dividend Date
Related Tickers
ONCO.CN Onco-Innova
1.2000
0.00%
BLAB.CN Britannia Life Sciences Inc.
0.0850
0.00%
MDMA.CN Pharmala Biotech Holdings Inc.
0.3100
+16.98%
MIR.V MedMira Inc.
0.1300
0.00%
BIOV.CN BioVaxys Technology Corp.
0.0600
-7.69%
MYND.CN MYND Life Sciences Inc.
0.0950
+35.71%
BCT.TO BriaCell Therapeutics Corp.
0.5900
-3.28%
RKV.V Rakovina Therapeutics Inc.
0.1750
-2.78%
VXL.V Vaxil Bio Ltd.
0.0100
0.00%
ONC.TO Oncolytics Biotech Inc.
1.2500
-3.85%